Hepaclear Sachet contains L-Ornithine L-Aspartate (3 gm), an amino acid compound used primarily for the management of hepatic encephalopathy and other liver-related disorders. This formulation acts by enhancing the detoxification of ammonia, a neurotoxic substance that accumulates in patients with liver dysfunction. L-Ornithine L-Aspartate facilitates the conversion of ammonia into urea and glutamine, thereby reducing elevated blood ammonia levels and improving cognitive function in affected individuals. Hepaclear is indicated as an adjunctive therapy in chronic liver diseases such as cirrhosis, where hyperammonemia contributes to neurological impairment. The sachet form allows for convenient oral administration and rapid absorption. It is generally well tolerated, with minimal adverse effects reported, although gastrointestinal disturbances such as nausea or diarrhea may occur in some patients. Hepaclear should be used under medical supervision, particularly in patients with severe hepatic impairment or those receiving other medications metabolized by the liver. Dosage and duration of treatment should be individualized based on clinical response and ammonia levels. Regular monitoring of liver function tests and neurological status is recommended to assess therapeutic efficacy and safety. Hepaclear represents a valuable option in the comprehensive management of hepatic encephalopathy and related metabolic disturbances.